Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study

Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study

Abstract Objective This study evaluated the antitumor activity and safety of pemigatinib in previously treated Chinese patients with advanced cholangiocarcinoma and fibroblast growth factor receptor 2 (FGFR2) fusions or rearrangements. Background Pemigatinib provided clinical benefits for previously...

Full description

Bibliographic Details
Main Authors: Guo‐Ming Shi, Xiao‐Yong Huang, Tian‐Fu Wen, Tian‐Qiang Song, Ming Kuang, Hai‐Bo Mou, Le‐Qun Bao, Hai‐Tao Zhao, Hong Zhao, Xie‐Lin Feng, Bi‐Xiang Zhang, Tao Peng, Yu‐Bao Zhang, Xiang‐Cheng Li, Hong‐Sheng Yu, Yu Cao, Lian‐Xin Liu, Ti Zhang, Wei‐Lin Wang, Jiang‐Hua Ran, Ying‐Bin Liu, Wei Gong, Ming‐Xia Chen, Lian Cao, Yang Luo, Yan Wang, Hui Zhou, Guo‐Huan Yang, Jia Fan, Jian Zhou
Format: Article
Language:English
Published: Wiley 2023-02-01
Series:Cancer Medicine
Subjects:
antitumor activity
cholangiocarcinoma
FGFR2 fusions or rearrangements
pemigatinib
phase II
Online Access:https://doi.org/10.1002/cam4.5273

Internet

https://doi.org/10.1002/cam4.5273

Similar Items